Thomas K. Baker

Microphysiological modeling of the Blood-CSF barrier for biopharmaceutical transport and sequestration: evaluation of PEG-induced accumulation and vacuolation in the choroid plexus epithelium

Jacquelyn Ann Brown, Monika G. Judge, David K. Schaffer, Dillon C. Gavlock et autres

Background: It has long been established that the central nervous system (CNS) is a highly privileged space, with the blood-brain barrier (BBB) acting as the gatekeeper that allows or denies access to the brain by nutrients, drugs, and toxins. The BBB, however, …

us (code pays fourni par la source)

Supplemental Table 2 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer

Shripad V. Bhagwat, Cecilia Mur, Matthew Vandekopple, Baohui Zhao et autres

In vivo single agent imlunestrant efficacy in ESR1-mutant and wild type xenograft and PDX breast cancer models.

Supplemental Table 1 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer

Shripad V. Bhagwat, Cecilia Mur, Matthew Vandekopple, Baohui Zhao et autres

Imlunestrant, elacestrant, and fulvestrant mediated ER degradation, PGR gene inhibition and cell proliferation inhibition in T-47D parental and T-47D ESR1-Y537N cells.

Supplemental Table 3 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer

Shripad V. Bhagwat, Cecilia Mur, Matthew Vandekopple, Baohui Zhao et autres

In vivo imlunestrant efficacy alone and in combination with abemaciclib, alpelisib, and everolimus in CDX breast cancer models.

Supplemental Table 4 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer

Shripad V. Bhagwat, Cecilia Mur, Matthew Vandekopple, Baohui Zhao et autres

Statistical analysis of imlunestrant and fulvestrant efficacy alone and in combination with abemaciclib, alpelisib, and everolimus in ESR1-wild type and mutant xenograft and PDX breast cancer models

Supplemental Figure 1 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer

Shripad V. Bhagwat, Cecilia Mur, Matthew Vandekopple, Baohui Zhao et autres

Biochemical and in vitro characterization of imlunestrant.

Supplemental Table 5 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer

Shripad V. Bhagwat, Cecilia Mur, Matthew Vandekopple, Baohui Zhao et autres

Statistical survival analysis and body weight change in MCF-7 intracranial model treated with imlunestrant or other SERDs.

Supplemental Figure 2 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer

Shripad V. Bhagwat, Cecilia Mur, Matthew Vandekopple, Baohui Zhao et autres

Imlunestrant PK/PD and uterotrophic activity.

Culture Is Key: Engaging Culturally and Linguistically Diverse Populations in Breast Cancer Screening in High Income Contexts: A Scoping Review

Karla Jaques, Thomas K. Baker, Mohammed Fazli, Mandy Williams et autres

BACKGROUND: Breast cancer is the most commonly diagnosed cancer in Australia and is the second highest cause of cancer mortality in Australian women. Screening in the form of mammography can significantly reduce mortality; however, research suggests that women from culturally and linguistically …

au (code pays fourni par la source)

Opportunities and insights from pharmaceutical companies on the current use of new approach methodologies in nonclinical safety assessment

Jacintha M. Shenton, Imein Bousnina, Michael Oropallo, Rhiannon M. David et autres

• Scientifically justified NAM-based regulatory submissions are accepted globally. • Key justifications are no relevant species, prior experience with the target, and disease severity. • Opportunity exists to scientifically justify NAM-based approaches in broader settings. • Knowledge sharing on suitable scenarios for …

us, gb, kr, ch, fr (code pays fourni par la source)

Supplemental Table 2 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer

Shripad V. Bhagwat, Cecilia Mur, Matthew Vandekopple, Baohui Zhao et autres

In vivo single agent imlunestrant efficacy in ESR1-mutant and wild type xenograft and PDX breast cancer models.

Data from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer

Shripad V. Bhagwat, Cecilia Mur, Matthew Vandekopple, Baohui Zhao et autres

Abstract Targeting of the estrogen receptor (ER) by antiestrogens is the standard of care for patients with ER+ HER2− advanced/metastatic breast cancer. Although antiestrogens that degrade ERα (fulvestrant) or block estrogen production (aromatase inhibitors) have improved patient outcomes, clinically important challenges remain …